Background {#Sec1}
==========

Cerebrovascular smooth muscle cell hyperplasia and direct migration from the media into the intima in the basilar artery play an important role in the pathogenesis of vascular remodeling, hypertension and strokes \[[@CR1]\]. It is generally accepted that the renin--angiotensin system contributes to cerebrovascular remodeling and strokes \[[@CR2]\]. Angiotensin II (AngII) plays a role in the cellular growth and survival of vascular smooth muscle cells (VSMCs) \[[@CR3], [@CR4]\]. It has been reported that blocking AngII type 1 receptor (AT1R) inhibited VSMC proliferation and migration \[[@CR5]\]. However, the precise molecular mechanisms by which AngII induces VSMC hyperplasia and subsequent cerebrovascular remodeling are still poorly understood.

Chloride (Cl^−^) is the most common and abundant anion in living organisms, with critical roles in various physiological processes \[[@CR6]\]. Several studies have demonstrated that dysregulated intracellular Cl^−^ concentration (\[Cl^−^\]~i~) is implicated in endothelial cell apoptosis, foam cell formation, vascular inflammation, hypertension and atherosclerosis \[[@CR7]--[@CR11]\]. Moreover, a recent study reported that reduction in serum chloride is an independent prognostic factor for acute heart failure \[[@CR12]\].

Cl^−^ movement is strictly regulated by the Cl^−^ channel (ClC) family \[[@CR6]\]. ClC-2 is almost ubiquitously expressed, including in human VSMCs \[[@CR13], [@CR14]\]. A previous study revealed that inhibition of ClC-2 abolished insulin-like growth factor-induced proliferation of porcine arterial smooth muscle cells \[[@CR15]\]. Nevertheless, the functional role of ClC-2 in cerebrovascular smooth muscle cell proliferation and basilar artery remodeling remains unknown.

Here, we found that AngII induced a reduction of \[Cl-\]~i~ in cerebrovascular smooth muscle cells, and this Cl^−^ efflux was dependent on ClC-2. This prompted us to speculate that ClC-2 may play a role in cerebrovascular remodeling. Our results suggest that inhibiting ClC-2 is promising for therapeutic approaches focused on preventing cerebrovascular remodeling and strokes.

Methods {#Sec2}
=======

Materials and reagents {#Sec3}
----------------------

Fetal bovine serum (FBS), streptomycin, penicillin, OptiMEM I medium and Lipofectamin 2000 were obtained from Invitrogen. Antibodies targeting ClC-2, ClC-3, PCNA, Ki67, p-β-catenin, β-catenin, lamin B, GAPDH and α-SMA were purchased from Santa Cruz Biotechnology. P-GSK-3β, GSK-3β, c-myc, survivin and cyclin D1 were from Cell Signaling Technology. Horseradish peroxide-conjugated rabbit anti-mouse or goat anti-rabbit secondary antibodies, and biotinylated goat anti-mouse IgG antibody were provided by Beyotime. Angiotensin II (AngII), bromodeoxyuridine (BrdU) antibody, rabbit anti-mouse-cy3 antibody, recombinant Wnt3a, and hematoxylin and eosin solutions were obtained from Sigma-Aldrich.

Cell culture {#Sec4}
------------

Human brain vascular smooth muscle cells (HBVSMCs) were purchased from Creative Bioarray (CSC-7824 W, NY, USA) and cultured in SuperCult Smooth Muscle Cell Medium (Creative Bioarray) containing 10% FBS, 100 μg/ml streptomycin and 100 U/ml penicillin in a humidified incubator with 5% CO~2~ and 95% O~2~ at 37 °C.

Cell transfection {#Sec5}
-----------------

ClC-2 or ClC-3 knockdown in HBVSMCs was achieved by transfection of human ClC-2 or ClC-3 siRNA (RiboBio Co., Ltd.). The sequence of the stealth siRNA duplex oligoribonucleotides against the human ClC-2 gene is 5'-GGATCGTTCAAGCGGCTC-3′ and against the ClC-3 gene is 5'-AAAGAGAGAATTCCAGGTT-3′. The negative siRNA oligonucleotides were used as a negative control. The siRNAs were diluted with OptiMEM I medium and transfected into cells with Lipofectamin 2000 according to the manufacturer's instructions.

Cell proliferation assay {#Sec6}
------------------------

The viability of HBVSMCs was measured with a Cell Counting Kit-8 (CCK-8; Dojindo Laboratories) according to the manufacturer's instructions. Briefly, HBVSMCs cells were seeded in 96-well plates (2 × 10^3^ cells/well) and rendered quiescent by replacing the medium with 0.2% FBS for 24 h. Then the cells were treated with AngII with or without ClC-2 siRNA treatment according to the experimental design. The medium was replaced with fresh medium containing 10 μl of CCK-8 reagent followed by incubation for 4 h at 37 °C in a 5% CO~2~ atmosphere. The absorbance value was read at 450--540 nm using a microplate reader (Bio-Tek).

At the same time, cell proliferation was measured based on the incorporation of BrdU during DNA synthesis in proliferating cells. Cells were treated with 50 mM BrdU for 4 h at 37 °C and then fixed with 4% paraformaldehyde. After permeabilization with 0.4% Triton X-100 in 2% HCI for 15 min, the cells were incubated with BrdU antibody at 4 °C overnight followed by treatment with biotinylated goat anti-mouse IgG antibody (Santa Cruz Biotechnology) for 1 h. The percentage of BrdU-positive cells was determined by counting the numbers of stained cells and total cells.

Wound-healing assay {#Sec7}
-------------------

Cell migration was observed using the wound-healing assay. The cell cycles of HBVSMCs pretreated with ClC-2 siRNA or negative siRNA were synchronized with 0.2% FBS for 24 h in 6-well plates. They reached full confluency, then AngII was added to the medium to induce migration. Cell monolayers were scraped with a sterile micropipette tip to create the 'wound'.

After 48 h, the wound area was observed using a light microscope (CKX41, Olympus). The wound widths were measured using ImageJ software (NIH, Version 1.41, NIH). The ability of cell migration was expressed as a percentage of the initial wound distance.

Invasion assay {#Sec8}
--------------

Cell invasion was examined using a transwell invasion assay (Costar) with 6.5-mm pores in a polycarbonate filter membrane. 1 × 10^5^ HBVSMCs that were pretreated with ClC-2 siRNA or negative siRNA in 100 μl medium with 0.5% FBS were added to the upper chamber in the presence or absence of AngII. 10% FBS was added to the medium in the lower chamber to induce cell invasion. After 48 h, the invading cells were fixed with 4% paraformaldehyde for 30 min and stained with crystal violet for 30 min. The images were photographed under a light microscope (CKX41) and quantified using ImageJ software.

Measurement of intracellular chloride concentration (\[Cl^−^\]~i~) {#Sec9}
------------------------------------------------------------------

\[Cl^−^\]i in HBVSMCs was measured using 6-methoxy-N-ethylquinolinium iodide (MEQ) as previously described \[[@CR9]\]. The cells were incubated with dihydro-MEQ (100 μM), which is the precursor of MEQ, in a Ringer's buffer solution containing 119 mM NaCl, 2.5 mM KCl, 1.0 mM NaH~2~PO~4~, 1.3 mM MgSO~4~, 2.5 mM CaCl~2~, 26 mM NaHCO~3~ and 11 mM glucose (pH 7.4) at room temperature in the dark for 30 min. Dihydro-MEQ was then oxidized to MEQ, which was quenched by Cl^−^. \[Cl^−^\]~i~ was monitored using MetaFluor Imaging software (Universal Imaging Systems) with excitation at 350 nm and emission at 435 nm. \[Cl^−^\]~i~ was calculated with the Stern--Volmer equation:$$\documentclass[12pt]{minimal}
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Western blotting {#Sec10}
----------------

HBVSMCs or cerebrovascular tissues were lysed using RIPA buffer (Beyotime) containing 1% protease and phosphatase inhibitors (Merck). Nuclear proteins were extracted using a Nuclear/Cytosol Fractionation Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. The protein concentration of each sample was determined using a bicinchoninic acid kit (BioRad). Equal amounts of protein were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) on 8--10% gels and then transferred onto nitrocellulose membranes (Millipore). The membranes were blocked with 5% non-fat milk powder in TBST consisting of 10 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-20 (pH 7.6) and incubated with the appropriate antibodies at 4 °C overnight. Afterwards, the blots were visualized with HRP-conjugated secondary antibodies followed detection with a chemiluminescence system (Thermo Fisher Scientific). Image quantification was performed using ImageJ software.

Quantitative real-time PCR {#Sec11}
--------------------------

Total RNA from HBVSMCs was isolated using an RNAeasy Mini Kit (Qiagen) according to the manufacturer's instructions. The concentration of the isolated RNA was determined via UV spectrometry. 1 μg of RNA was reverse-transcribed to cDNA using a first strand cDNA synthesis kit (Thermo Fisher Scientific Inc.). mRNA expression was examined using Fast SYBR Green Master Mix Kit (Applied Biosystems) with an ABI 7500 RT-PCR System (Applied Biosystems). The primer sequences were:

ClC-2: 5'-AGCACAGGGTGTGAAAGTCC-3′ and 5'-TCATTGGCATTTGTCGTCGC-3'.

Wnt3a: 5'-GGAGCAGGACTCCCACCTAA-3′ and 5′- GCCACCAGAGAGGAGACACT-3'.

Wnt5a: 5'-AAGCAGACGTTTCGGCTACA-3′ and 5'-TTTCCAACGTCCATCAGCGA-3'.

GAPDH: 5'-GGGCACGAAGGCTCATCATT-3′ and 5'-AGAAGGCTGGGGCTCATTTG-3'.

Target gene expression (2^−ΔΔCt^) was normalized to endogenous GAPDH expression.

Animal studies {#Sec12}
--------------

Male, 12-week old, 20- to 25-g C57BL/6 mice were purchased from Jackson Laboratory. Mice were randomized to inject with Lacz adenovirus (10^9^ pfu/mouse) or ClC-2 shRNA adenovirus (10^9^ pfu/mouse; Sunbio Medical Biotechnology) via tail vein and infused with AngII. After 7 days of adenovirus infection, the test mice were anesthetized with isoflurane and infused with AngII (1.5 mg/kg/day, 4 weeks, subcutaneously by osmotic minipumps, Model 1002, Alza Corp.). The control animals were sham-operated and given saline. Systolic blood pressure (SBP) was measured in conscious mice by tail-cuff plethysmography (BP-98A, Softron Co.) during a fixed period of the day (8:00 to 10:00 a.m.).

Histological analyses {#Sec13}
---------------------

The basilar arteries were isolated, embedded in paraffin and cut into 4-μm sections. The sections were heated for 30 min at 65 °C, dewaxed in xylene, and rehydrated with 100, 95, 70 and 50% alcohols at room temperature for 1 min. The endogenous peroxidase activity and non-specific staining were respectively blocked by 5% H~2~O~2~ and 2% nonimmune serum solution. The sections were stained with hematoxylin and eosin for histopathological examination and observed under a light microscope (CKX41). The circumferences (C) of external and internal elastic lamina were measured with ImageJ software. External (De) and internal (Di) diameters were calculated as C/π, and then the medial cross-sectional area (CSA) was obtained as:$$\documentclass[12pt]{minimal}
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For immunofluorescence staining of α-SMA, the sections were incubated with an antibody against α-SMA diluted in nonimmune serum solution overnight at 4 °C. After rinsing with PBS 3 times, the sections were incubated with rabbit anti-mouse-cy3 secondary antibody for 1 h at room temperature. Immunofluorescence was observed and analyzed using a confocal system (FV1000, Olympus) and ImageJ software.

Statistical analysis {#Sec14}
--------------------

Results were obtained from at least four independent experiments. All data were presented as means ± standard error of mean (SEM). Statistical analysis was performed with SPSS 18.0 software (SPSS Inc.) using two-tailed Student t test or one-way ANOVA, followed by the Bonferroni multiple comparison test. A *p* value less than 0.05 was considered statistically significant.

Results {#Sec15}
=======

ClC-2 knockdown reversed AngII-induced decrease in \[Cl^−^\]~i~ levels {#Sec16}
----------------------------------------------------------------------

To explore the relationship between cerebrovascular proliferation and \[Cl^−^\]~i~, HBVSMCs were treated with various concentrations of AngII and the cell viability and \[Cl^−^\]~i~ were measured. Figure [1a](#Fig1){ref-type="fig"} and [b](#Fig1){ref-type="fig"} show that the viability of HBVSMCs was increased and the \[Cl^−^\]~I~ was decreased dose-dependently by AngII treatment. Intriguingly, the cell viability after AngII challenge negatively correlated with \[Cl^−^\]~i~ (Fig. [1c](#Fig1){ref-type="fig"}).Fig. 1ClC-2 knockdown inhibited the AngII-induced efflux of Cl^−^ in HBVSMCs. **a** HBVSMCs were treated with angiotensin II (AngII) at different concentrations (10^− 9^, 10^− 8^ 10^− 7^ and 10^− 6^ M) for 48 h. Cell viability was determined using the CCK-8 assay. **b** Intracellular Cl^−^ concentration \[Cl^−^\]~i~ was examined using an MEQ fluorescence probe. **c** The correlation between \[Cl^−^\]~i~ and cell viability was analyzed. **d** and **e** -- The expression of ClC-2 in the cells treated as described in (**a**) was examined using western blotting (**d**) and quantitative real-time PCR (**e**). **f** Cells were treated with ClC-2 siRNA (20 nM) or negative siRNA for 48 h before AngII incubation (10^− 7^ M) for a further 48 h. \[Cl^−^\]~i~ was examined. \**p* \< 0.05, \*\**p* \< 0.01 vs. control, ^\#\#^*p* \< 0.01 vs. AngII alone, *n* = 6

The results also showed that AngII markedly increased ClC-2 expression, suggesting that ClC-2 may be involved in AngII-mediated changes in \[Cl^−^\]~i~ (Fig. [1d](#Fig1){ref-type="fig"} and [e](#Fig1){ref-type="fig"}). To test this assumption, HBVSMCs were transfected with ClC-2 siRNA before AngII treatment. Two independent ClC-2 siRNA, marked siClC-2-1 and siClC-2-2, were used (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A and B). siClC-2-1 at 20 nM significantly decreased endogenous ClC-2 expression by more than 75% (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A). Therefore, si-1 targeting ClC-2 was used in subsequent experiments. In addition, ClC-2 knockdown did not change the expression of ClC-3 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1C). Although ClC-2 inhibition produced no effect on \[Cl^−^\]~i~ under basal levels, the AngII-induced decrease in \[Cl^−^\]~i~ was markedly reversed after ClC-2 siRNA treatment (Fig. [1f](#Fig1){ref-type="fig"}). Downregulation of ClC-3 did not affect the increased Cl^−^ efflux (Additional file [1](#MOESM1){ref-type="media"}: Figure S2). These data indicate that AngII-induced efflux of Cl^−^ is at least partially through the ClC-2 chloride channel.

ClC-2 inhibition attenuated AngII-induced HBVSMC proliferation {#Sec17}
--------------------------------------------------------------

Since ClC-2-dependent Cl^−^ efflux may be associated increased cell viability after AngII treatment, we next investigated the effect of ClC-2 siRNA on HBVSMC proliferation. The CCK-8 assay showed that ClC-2 knockdown had no significant effect on cell viability in the absence of AngII. However, AngII impact on the cell viability of HBVSMCs was markedly inhibited by ClC-2 siRNA (Fig. [2a](#Fig2){ref-type="fig"}). BrdU incorporation also revealed that ClC-2 inhibition prevented AngII-induced HBVSMC proliferation (Fig. [2b](#Fig2){ref-type="fig"}). The expressions of the proliferation markers, PCNA and Ki67, both increased after incubation with AngII. However, knockdown of ClC-2 was associated with reduced expression of these proliferation markers (Fig. [2c](#Fig2){ref-type="fig"} and [d](#Fig2){ref-type="fig"}).Fig. 2Lack of ClC-2 reduced AngII-induced HBVSMC proliferation. **a** and **b** Cells were transfected with ClC-2 siRNA (siClC-2; 20 nM) or negative siRNA (negative; 20 nM) for 48 h in prior to angiotensin II (AngII) treatment (10^− 7^ M) for another 48 h. Cell proliferation was determined using the CCK-8 assay (**a**) and BrdU incorporation (**b**). **c** and **d** The protein expressions of PCNA (**c**) and Ki67 (**d**) were detected using western blotting. \*\**p* \< 0.01 vs. control, ^\#\#^*p* \< 0.01 vs. AngII alone, *n* = 5

Lack of ClC-2 decreased AngII-induced motility of HBVSMCs {#Sec18}
---------------------------------------------------------

VSMC motility plays an important role in vascular remodeling, so we measured the migratory and invasive ability of HBVSMCs. Our results showed that AngII improved the ability of HBVSMCs to close the wound. However, wound closure and migration distance were significantly attenuated by ClC-2 siRNA (Fig. [3a](#Fig3){ref-type="fig"} and [b](#Fig3){ref-type="fig"}).Fig. 3ClC-2 downregulation prevented AngII-induced HBVSMC migration and invasion. **a** HBVSMCs transfected with ClC-2 siRNA (siClC-2; 20 nM) or negative siRNA (negative; 20 nM) were subjected to angiotensin II (AngII) treatment (10^− 7^ M). The wound healing assay was performed. Representative images are shown (× 100). **b** The quantification results for the wound closure. **c** HBVSMC migration was examined via transwell analysis. Representative images are shown (× 100). **d** The columns represent the relative numbers of invasive cells. \*\**p* \< 0.01 vs. control, ^\#\#^*p* \< 0.01 vs. AngII alone, *n* = 6

The transwell invasion assay, an alternative means to determine cell movement, revealed that ClC-2 downregulation also decreased the invasion of HBVSMCs compared that of cells treated with AngII (Fig. [3c](#Fig3){ref-type="fig"} and [d](#Fig3){ref-type="fig"}). These results imply that ClC-2 knockdown inhibits the migration and invasion of HBVSMCs.

ClC-2 downregulation blocked the activation of Wnt/β-catenin signaling induced by AngII {#Sec19}
---------------------------------------------------------------------------------------

The Wnt/β-catenin pathway plays an indispensable role in cell proliferation, followed by transcriptional activation of target genes in the nucleus \[[@CR16]\]. Western blotting showed that incubation with AngII resulted in a marked increase in β-catenin phosphorylation, which was inhibited by ClC-2 siRNA (Fig. [4a](#Fig4){ref-type="fig"}). AngII also promoted β-catenin nuclear translocation, as evidenced by the increased amount of β-catenin in the nucleus and the reduced amount in the cytoplasm, indicating the activation of β-catenin. However, ClC-2 downregulation significantly inhibited the nuclear translocation of β-catenin (Fig. [4b](#Fig4){ref-type="fig"} and [c](#Fig4){ref-type="fig"}). β-catenin activation is mediated by the disruption of the GSK-3β--axin--β-catenin complex, which is dependent on GSK-3β phosphorylation \[[@CR17]\].Fig. 4ClC-2 inhibition attenuated the AngII-induced activation of Wnt/β-catenin signaling. **a** through **f** HBVSMCs were transfected with ClC-2 siRNA (siClC-2; 20 nM) or negative siRNA (negative; 20 nM) and then stimulated with angiotensin II (AngII; 10^− 7^ M) for 48 h. Shown are the western blotting results for β-catenin phosphorylation (**a**), β-catenin cytosol (**b**) and nuclear protein (**c**) levels, GSK-3β phosphorylation (**d**), and survivin (**e**) and cyclin D1 (**f**) protein expression. **g** Quantitative real-time PCR analysis of Wnt3a and Wnt5a mRNA expression. **h** The cells were treated with recombinant Wnt3a (100 ng/ml) for 48 h. Wnt3a expression was examined using quantitative real-time. **i** Viability of HBVSMCs transfected with ClC-2 siRNA followed by co-incubation with recombinant Wnt3a and AngII. \*\**p* \< 0.01 vs. control, ^\#\#^*p* \< 0.01 vs. AngII alone, ^\$\$^*p* \< 0.01 vs. AngII+siClC-2, *n* = 4

As expected, similarly to the inhibition of β-catenin activation, AngII-induced phosphorylation of GSK-3β was also blocked by ClC-2 siRNA (Fig. [4d](#Fig4){ref-type="fig"}). The downstream target genes of Wnt/β-catenin signaling were determined, including survivin and cyclin D1. The results showed that AngII induced the expression of survivin and cyclin D1 in HBVSMCs, whereas CIC-2 inhibition was associated with reduced expression of these genes (Fig. [4e](#Fig4){ref-type="fig"} and [f](#Fig4){ref-type="fig"}).

Of the 19 known Wnt ligands, Wnt3a and Wnt5a have been associated with β-catenin activation and VSMC proliferation \[[@CR9], [@CR18], [@CR19]\]. Interestingly, ClC-2 knockdown dramatically inhibited the increase in Wnt3a mRNA expression induced by AngII, but had no effect on decreased Wnt5a expression (Fig. [4g](#Fig4){ref-type="fig"}), indicating that the alteration of Wnt3a may underlie the effect of ClC-2 on Wnt/β-catenin signaling.

To further understand the role of Wnt3a in this process, we measured the viability of HBVSMCs exposed to recombinant Wnt3a (100 ng/ml). Wnt3a mRNA expression significantly increased after recombinant Wnt3a treatment (Fig. [4h](#Fig4){ref-type="fig"}). The CCK-8 assay showed that the effect of ClC-2 inhibition on cell viability was completely abrogated by Wnt3a treatment (Fig. [4i](#Fig4){ref-type="fig"}).

ClC-2 deficiency ameliorated cerebrovascular remodeling {#Sec20}
-------------------------------------------------------

We further examined the effect of ClC-2 downregulation on cerebrovascular remodeling in vivo. We established an AngII-induced hypertension model with a gene approach. C57BL/6 mice were injected with ClC-2-shRNA adenovirus or Lacz adenovirus before AngII infusion. Consistent with the increased ClC-2 expression in AngII-treated HBVSMCs, ClC-2 expression in the basilar arteries of AngII-treated mice also significantly increased. Injection of ClC-2-shRNA adenovirus inhibited the increased expression of ClC-2 (Additional file [1](#MOESM1){ref-type="media"}: Figure S3A). SBP gradually increased after AngII infusion over a 4-week period. However, the elevation of SBP was inhibited in mice infected with ClC-2-shRNA adenovirus (Additional file [1](#MOESM1){ref-type="media"}: Figure S3B). Hematoxylin and eosin staining of basilar arteries of AngII-treated mice showed significant changes compared with sham mice. AngII infusion dramatically increased media thickness and deceased internal lumen diameter, leading to enhanced medial CSA, a typical feature of hypertrophic remodeling. However, these morphological changes were inhibited in mice infected with ClC-2 shRNA adenovirus (Fig. [5a](#Fig5){ref-type="fig"} and [b](#Fig5){ref-type="fig"}). α-SMA immunofluorescence staining of the smooth muscle layer further supported the inhibitory effect of ClC-2 downregulation on AngII-induced increase in the media thickness of basilar arteries (Fig. [5c](#Fig5){ref-type="fig"} and [d](#Fig5){ref-type="fig"}). Moreover, the AngII-induced increase in β-catenin and GSK-3β phosphorylation and survivin and cyclin D1 expression in basilar artery lysates were significantly inhibited in mice lacking ClC-2 (Fig. [5e](#Fig5){ref-type="fig"}--[h](#Fig5){ref-type="fig"}).Fig. 5ClC-2 deficiency blocked cerebrovascular remodeling. **a** C57BL/6 mice were injected with ClC-2-shRNA adenovirus (sh-ClC-2) or Lacz adenovirus before AngII infusion. Representative images of hematoxylin and eosin staining of basilar arteries. **b** Vascular remodeling was evaluated based on the cross-sectional area (CSA). **c** Representative images of immunofluorescence staining for α-SMA expression. **d** Bar graph showing the the relative fluorescence density values for α-SMA expression. **e** through **h** β-catenin (**e**) and GSK-3β (**f**) phosphorylation, and survivin (**g**) and cyclin D1 (**h**) protein expression were determined via western blotting. \**p* \< 0.01, \*\**p* \< 0.01 vs. Lacz, ^\#\#^*p* \< 0.01 vs. AngII+Lacz, *n* = 8 mice in each group

Discussion {#Sec21}
==========

Aberrant proliferation of cerebrovascular smooth muscle cells, a major risk factor for cerebrovascular remodeling, increases wall thickness and decreases lumen diameter, precipitating the occurrence of strokes \[[@CR20]\]. Therefore, inhibiting hyperplasia of cerebrovascular smooth muscle cells may be a viable strategy for preventing strokes.

Our key findings were:AngII-induced HBVSMC proliferation is associated with an enhanced ClC-2-mediated Cl^−^ efflux. Both are dose dependent.Knockdown of ClC-2 blocked the AngII-induced proliferation and motility of HBVSMCs by inhibiting Wnt/β-catenin signaling.In vivo downregulation of ClC-2 could effectively prevent basilar artery remodeling.

These findings indicate an important role for ClC-2 in the AngII-induced proliferation of cerebrovascular smooth muscle cells.

Increasing lines of evidence have suggested that water influx may contribute to cell swelling during the early phase of proliferation \[[@CR2], [@CR15]\]. An increase in cell volume can trigger a 'regulatory volume decrease' (RVD) process through the activation of ClCs or transporters. This promotes Cl^−^ efflux out of cells to balance water influx and maintains normal cell volume \[[@CR6], [@CR21]\]. Thus, ClCs play a critical role in cell proliferation.

There are 9 members in the ClC family: ClC-1, ClC-2, ClC-Ka, ClC-Kb, ClC-3, ClC-4, ClC-4, ClC-5, ClC-6 and ClC-7 \[[@CR14]\]. ClC-2, initially isolated from the rat heart and brain, can regulate cell volume and control the response to swelling \[[@CR22], [@CR23]\]. However, its function in VSMC proliferation is still poorly understood.

Here, we observed that AngII-induced HBVSMC proliferation was accompanied by an increase in ClC-2 expression. More importantly, the decrease in \[Cl^−^\]~i~ induced by AngII was abolished when ClC-2 was silenced. Accordingly, we speculated that the activation of the ClC-2 channel might be associated with AngII-induced cerebrovascular smooth muscle cell proliferation. Indeed, we found that lowering ClC-2 expression significantly reduced AngII-induced HBVSMC proliferation, migration and invasion.

However, it has been reported that transgenic ClC-3 knockout mice also demonstrated inhibited VSMC proliferation and vascular remodeling \[[@CR3]\]. In addition, a lack of TMEM-16A, a member of the Ca^2+^-activated Cl^−^ channel, contributed to the cerebrovascular remodeling, revealing an opposite effect on cell proliferation \[[@CR24]\]. The discrepancy may be related to complicated mechanisms and differences in cell type.

Knockdown of ClC-3 is reported to attenuate proliferation in A10 VSMCs, whereas TMEM-16A downregulation promotes proliferation in rat basilar artery smooth muscle cells \[[@CR3], [@CR24]\]. In our study, normal HBVSMCs were used for the proliferation analysis. Additional studies to further investigate the different roles of ClCs in different cell types are warranted.

Another significant finding of our study is that the inhibitory effect of ClC-2 downregulation on cerebrovascular smooth muscle cell proliferation is associated with inactivation of the Wnt/β-catenin pathway. It is well known that Wnt/β-catenin signaling is one of most important regulators of cell proliferation, migration, adhesion and survival \[[@CR16]\]. Previous studies have shown that β-catenin expression increased in animal models of intimal hyperplasia, so a critical role for the Wnt/β-catenin pathway in VSMC hyperplasia has been considered \[[@CR17], [@CR25]\].

Originally functioning as the key mediator of Wnt signaling, β-catenin expression is tightly regulated by a multiprotein complex that targets for β-catenin degradation, e.g., GSK-3β \[[@CR18]\]. On the other hand, β-catenin can be also activated by phosphorylation at the C-terminal at serine 675, which leads to β-catenin nuclear translocation \[[@CR26]\].

Consistent with previous reports showing that AngII could regulate β-catenin activation in VSMCs \[[@CR27], [@CR28]\], we found that AngII caused β-catenin activation and GSK-3β phosphorylation, which could lead to β-catenin nuclear accumulation in HBVSMCs. However, the total protein expression of β-catenin remained unchanged after the AngII challenge. ClC-2 knockdown significantly attenuated β-catenin activation and GSK-3β phosphorylation. We also noted that ClC-2 inhibition had no effect on AngII-induced HBVSMC proliferation after recombinant Wnt3a treatment, further supporting the critical role of the Wnt/β-catenin pathway in the impact of ClC-2. Upon β-catenin translocation, nuclear β-catenin facilitates the transcriptional activation of target genes in the nucleus, such as survivin and cyclin D1 \[[@CR29], [@CR30]\]. These are both important regulators of the cell cycle. Survivin orchestrates multiple networks promoting cell proliferation and inhibiting apoptosis \[[@CR31]\]. Cyclin D1 is responsible for inducing G1/S transition and its inhibition induces G1/S phase arrest \[[@CR32]\].

Here, our data suggest that a lack of ClC-2 inhibited the AngII-induced increase in survivin and cyclin D1 expression. This indicates that inhibition of HBVSMC proliferation by ClC-2 downregulation may be mediated by the reduced expression of survivin and cyclin D1.

Conclusions {#Sec22}
===========

This study demonstrates that inhibition of ClC-2-mediated Cl^−^ efflux limits AngII-induced proliferation of cerebrovascular smooth muscle cells through inactivation of the Wnt/β-catenin pathway. These results suggest that inhibition of ClC-2 may be an attractive therapeutic approach for prevention of cerebrovascular remodeling and strokes.
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Additional file 1:**Figure S1.** Downregulation of ClC-2 did not alter ClC-3 expression. A and B -- HBVSMCs were transfected with ClC-2 siRNA, designated siClC-2-1 (A) and siClC-2-2 (B), for 48 h. Western blotting analysis of ClC-2 protein expression. C -- The protein expression of ClC-3 was also determined via western blotting. \*\**p* \< 0.01 vs. control, n = 6. **Figure S2.** Knockdown of ClC-3 had no effect on the AngII-induced efflux of Cl^−^. A and B -- HBVSMCs were transfected with ClC-3 siRNA, designated siClC-3-1 (A) and siClC-3-2 (B), for 48 h. Western blotting analysis of ClC-3 protein expression. C -- Cells were treated with ClC-3 siRNA (20 nM) for 48 h before AngII incubation (10^-7^ M) for a further 48 h. \[Cl^-^\]~i~ was assessed. \*\**p* \< 0.01 vs. control, *n* = 6. **Figure S3.** ClC-2 downregulation inhibited the AngII-induced increase in blood pressure. A -- C57BL/6 mice were injected with ClC-2-shRNA adenovirus (sh-ClC-2) or Lacz adenovirus before AngII infusion. The expression of ClC-2 in the basilar arteries was examined using western blotting. B -- Average systolic blood pressure (SBP) was measured using the non-invasive tail-cuff method. \*\**p* \< 0.01 vs. Lacz, ^\#\#^*p* \< 0.01 vs. AngII+Lacz, *n* = 8 mice in each group. (DOCX 134 kb)
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